×
Vaxxinity Total Liabilities 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity total liabilities from 2020 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
View More
Vaxxinity Total Liabilities 2020-2023 | VAXX
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Vaxxinity total liabilities from 2020 to 2023. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$139.4B
Bristol Myers Squibb (BMY)
$115.2B
Gilead Sciences (GILD)
$114.5B
Vertex Pharmaceuticals (VRTX)
$104.5B
CSL (CSLLY)
$84.4B
Regeneron Pharmaceuticals (REGN)
$78.6B
GSK (GSK)
$70.4B
Argenex SE (ARGX)
$37.4B
Alnylam Pharmaceuticals (ALNY)
$30.1B
BioNTech SE (BNTX)
$27.6B
Biogen (BIIB)
$21.9B
Illumina (ILMN)
$20.8B
Moderna (MRNA)
$16.2B
Genmab (GMAB)
$13.9B
Incyte (INCY)
$13.4B
BioMarin Pharmaceutical (BMRN)
$12.7B
Insmed (INSM)
$12.5B
Sarepta Therapeutics (SRPT)
$11.9B
Bio-Techne Corp (TECH)
$11.4B
Exact Sciences (EXAS)
$10.5B
Vaxcyte (PCVX)
$10.4B
QIAGEN (QGEN)
$10.2B
Swedish Orphan Biovitrum (BIOVF)
$10.1B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.1B
Intra-Cellular Therapies (ITCI)
$8.9B
Roivant Sciences (ROIV)
$8.8B
Ascendis Pharma (ASND)
$8.4B
Repligen (RGEN)
$8B
Jazz Pharmaceuticals (JAZZ)
$7.5B